$INTI
Inhibitor Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224030381 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $493.6K $345.4K
YoY Change -1.28% -32.08%
% of Gross Profit
Research & Development $319.6K $239.8K
YoY Change 22.57% 2.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $813.2K $585.1K
YoY Change 7.07% -21.19%
Operating Profit -$813.2K -$585.1K
YoY Change 7.07% -21.19%
Interest Expense $82.24K $83.46K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$731.0K -$501.7K
YoY Change 10.75% -23.35%
Income Tax
% Of Pretax Income
Net Earnings -$731.0K -$501.7K
YoY Change 9.96% -23.35%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 172.3M shares 172.3M shares
Diluted Shares Outstanding 172.3M shares 172.3M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.378M $7.099M
YoY Change -33.14% -29.72%
Cash & Equivalents $6.400M $7.100M
Short-Term Investments
Other Short-Term Assets $73.14K $74.63K
YoY Change 4.49% 28.65%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.451M $7.173M
YoY Change -32.85% -29.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $6.451M $7.173M
Total Long-Term Assets $0.00 $0.00
Total Assets $6.451M $7.173M
YoY Change -32.85% -29.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.706K $18.80K
YoY Change -98.17% 60.03%
Accrued Expenses $42.85K $16.72K
YoY Change -32.29% -47.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.56K $35.53K
YoY Change -71.52% -19.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $3.000M $3.000M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.56K $35.53K
Total Long-Term Liabilities $3.000M $3.000M
Total Liabilities $3.045M $3.036M
YoY Change -3.54% -0.27%
SHAREHOLDERS EQUITY
Retained Earnings -$50.70M -$49.97M
YoY Change 6.48% 6.43%
Common Stock $17.23K $17.23K
YoY Change -99.97% -99.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.407M $4.138M
YoY Change
Total Liabilities & Shareholders Equity $6.451M $7.173M
YoY Change -32.85% -29.38%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$731.0K -$501.7K
YoY Change 9.96% -23.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$720.4K -$583.1K
YoY Change 28.65% -14.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -720.4K -583.1K
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000
Net Change In Cash -720.4K -583.1K
YoY Change 28.65% -14.58%
FREE CASH FLOW
Cash From Operating Activities -$720.4K -$583.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1741170 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8839912 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
12250 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-654521 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7114475 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7114475 usd
us-gaap Net Income Loss
NetIncomeLoss
-1186401 usd
us-gaap Net Income Loss
NetIncomeLoss
-1194117 usd
us-gaap Share Based Compensation
ShareBasedCompensation
40250 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12250 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-34618 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
34107 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-629637 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-223923 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1741170 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1439897 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
411000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-411000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1850897 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11951224 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7098742 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10100327 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7100000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zDgNDtwwpPfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
290000 shares
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.07
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
20000.00 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0433 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2918 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd

Files In Submission

Name View Source Status
0001493152-24-030381-index-headers.html Edgar Link pending
0001493152-24-030381-index.html Edgar Link pending
0001493152-24-030381.txt Edgar Link pending
0001493152-24-030381-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
inti-20240630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
inti-20240630_cal.xml Edgar Link unprocessable
inti-20240630_def.xml Edgar Link unprocessable
inti-20240630_pre.xml Edgar Link unprocessable
inti-20240630_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed